Abstract:9106 Background: ASK120067 (Limertinib) is a newly developed third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) targeting both sensitizing EGFR and EGFR T790M mutations. This study aimed to evaluate the efficacy and safety of ASK120067 in patients with locally advanced or metastatic EGFR T790M mutated non-small cell lung cancer (NSCLC). Methods: This study was a single-arm, open-label, phase 2b study conducted at 62 hospitals across China. Patients with locally advanced or metastatic NSCLC with centrally confirmed EGFR T790M mutations in tumor tissue or blood plasma who progressed after first or second generation EGFR TKIs or with primary EGFR T790M mutations were enrolled. Patients received ASK120067 160mg orally twice daily, until disease progression, or unacceptable toxicity. The primary endpoint was objective response rate (ORR) assessed by Independent Review Committee (IRC) per RECIST1.1. Secondary endpoints included disease control rate (DCR), progression-free survival (PFS), duration of response (DOR), overall survival (OS), and safety. Safety was assessed according to CTCAE 4.03. Results: Between June 24th, 2019 and Feb 25th, 2021 301 patients were enrolled and received ASK120067 treatment. All patients entered the full analysis set (FAS) and safety set (SS). A total of 99 (32.9%) patients had central nervous system (CNS) metastases at baseline. By the data cutoff date on Sep 9th, 2021, 76 (25.2%) remained on treatment. The median follow-up time was10.4 (range 0.3-26.3) months. Based on FAS, the IRC-assessed ORR was 68.8% (95%CI 63.2%-74.0%) and DCR was 92.4% (95%CI 88.8%-95.1%). The median PFS was 11.0 (95%CI 9.7-12.4) months, median DOR was 11.1 (95%CI 9.6-13.8) months, and median OS was not reached (NR) (95%CI 19.7 months-NR). Objective responses were achieved across all pre-specified subgroups. For 99 patients with CNS metastases, the ORR was 64.6% (95%CI 54.4%-74.0%), median PFS was 9.7 (95%CI 5.9-11.6) months, and median DOR was 9.6 (95%CI 8.1-15.2) months. For 41 patients who had evaluable CNS lesion, the confirmed CNS-ORR was 56.1% (95%CI, 39.7%-71.5%) and median CNS-PFS was 10.6 (95%CI 5.6-NE) months. In SS, 289 (96.0%) patients experienced at least one adverse drug reaction (ADR), with the most common being diarrhea (81.7%), anemia (32.6%), rash (29.9%) and appetite decrease (28.2%). Grade ≥3 ADRs occurred in 104 (34.6%) patients, and the most common included diarrhea (13.0%), hypokalemia (4.3%), anemia (4.0%) and rash (3.3%). ADRs leading to dose interruption and dose discontinuation occurred 24.6% and 2% of patients, respectively. No ADR leading to death occurred. Conclusions: ASK120067 demonstrated promising efficacy and an acceptable safety profile for the treatment of patients with locally advanced or metastatic EGFR T790M mutated NSCLC. Clinical trial information: NCT03502850.

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)

1439P Brain Radiotherapy Combined with Camrelizumab and Platinum-Based Chemotherapy As First-Line Treatment for Advanced NSCLC with Brain Metastases: A Multicenter, Open-Label, Single-Arm, Phase II Study

A phase II study of anlotinib combined with temozolomide in the treatment of patients with recurrent glioblastoma.

Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review

Whole-Brain Radiotherapy Combined with Anlotinib for Multiple Brain Metastases from Non-small Cell Lung Cancer Without Targetable Driver Mutation: A Single-Arm, Phase II Study

Open, Single Arm Trial of Erlotinib As the 2nd/3rd Line Treatment in Advanced or Recurrent Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Wild Type and C-Met Negative Expression (ml28941, C-Tong 1306)

Whole-brain Radiotherapy with and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a Multicenter, Open-Label, Randomized, Controlled Phase III Trial

Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR -mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer

Randomized Phase 3 Study of First-Line AZD3759 (zorifertinib) Versus Gefitinib or Erlotinib in EGFR-mutant (egfrm+) Non–small-Cell Lung Cancer (NSCLC) with Central Nervous System (CNS) Metastasis.

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC)

Erlotinib As Neoadjuvant Treatment in Patients with Iiia-N2 Non-Small Cell Lung Cancer(Nsclc) with Activating Epidermal Growth Factor Receptor (egfr) Mutation (nct01217619, Estern)

Gefitinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Brain Metastasis

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study

Final Overall Survival Results from a Randomised, Phase III Study of Erlotinib Versus Chemotherapy As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-cell Lung Cancer (OPTIMAL, CTONG-0802).

Efficacy and safety of ASK120067 (limertinib) in patients with locally advanced or metastatic EGFR T790M-mutated non–small cell lung cancer: A multicenter, single-arm, phase IIb study.

CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non–small cell lung cancer.

Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study

Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trial

Efficacy of lazertinib for symptomatic or asymptomatic brain metastases in treatment-naive patients with advanced EGFR mutation-positive non-small cell lung cancer: Protocol of an open-label, single-arm phase II trial

A Randomized Placebo-Controlled Phase III Study of Intercalated Erlotinib with Gemcitabine/platinum in First-Line Advanced Non-Small Cell Lung Cancer (NSCLC): FASTACT-II.